PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer

Journal article

Peer reviewed

Charlie Gourley, Heather J. Dalton, Susana N. Banerjee, Joseph Buscema, Michelle Lockley, Jonathan Krell and Bradley J. Monk

Journal of clinical oncology, Vol.36(15_suppl), pp.TPS5612-TPS5612

05/20/2018

Metrics

1 Record Views

Title: PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer
Creators: Charlie Gourley - Edinburgh Cancer Research
Heather J. Dalton - Arizona Oncology
Susana N. Banerjee - Royal Marsden NHS Foundation Trust
Joseph Buscema - Greater Baltimore Medical Center
Michelle Lockley - University College London
Jonathan Krell - Imperial College Healthcare NHS Trust
Bradley J. Monk - Dignity Health
Publication Details: Journal of clinical oncology, Vol.36(15_suppl), pp.TPS5612-TPS5612
Identifiers: 991006263892102656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article